Science Daily: Pharmacology News

AUGUST 17, 2023

A single injection of a novel CRISPR gene-editing treatment safely and efficiently removes SIV -- a virus related to the AIDS-causing agent HIV -- from the genomes of non-human primates, scientists now report.

Virus 189

Virus Treatment Clinical Trials FDA 189

BioPharma Drive: Drug Pricing

SEPTEMBER 12, 2024

Spun out of research at Nationwide Children’s Hospital, Vironexis claims it will be the first company to start a study testing a cancer drug delivered via the adeno-associated viruses commonly used in genetic medicines.

Therapies 284

Therapies Virus Trials Hospitals 284

BioPharma Drive: Drug Pricing

SEPTEMBER 19, 2024

According to the company, the results are the first time an antiviral drug has reduced transmission of a respiratory virus in a global Phase 3 trial.

Virus 260

Virus Trials Drugs 260

Drugs.com

JUNE 10, 2024

Food and Drug Administration on Friday has for the first time approved the use of a respiratory syncytial virus (RSV) vaccine for people in their 50s who are at increased risk for the illness. MONDAY, June 10, 2024 -- The U.S. Drugmaker GSK's.

Vaccine 264

Vaccine Virus FDA Drugs 264

Drugs.com

MARCH 5, 2024

TUESDAY, March 5, 2024 -- Many people protected by drugs that prevent HIV infection quit using them, upping their vulnerability to the virus that causes AIDS, new research shows.The drug combo known as pre-exposure prophylaxis (PrEP) is now a.

Virus 277

Virus Research Drugs 277

Covalent Modifiers

OCTOBER 12, 2024

2024 121 (42) e2409166121 [link] Chikungunya virus (CHIKV) is a mosquito-borne alphavirus that has been responsible for numerous large-scale outbreaks in the last twenty years. Streblow and Nathaniel J. Moorman and Mark T. Heise and Timothy M. Willson and Konstantin I. Popov and Kenneth H. Pearce Proc. hit rate).

Virus 162

Virus Biochemical Assays FDA Approval FDA 162

BioPharma Drive: Drug Pricing

MAY 7, 2024

The company is using what it claims is the largest database of viral protein structures to unearth medicines for a range of diseases, said CEO and Flagship origination partner Lovisa Afzelius.

Virus 167

Virus Disease Drugs 167

Drugs.com

SEPTEMBER 4, 2024

4, 2024 -- Current vaccines against mpox were designed to fight an older, rarer cousin of the virus, smallpox.Now, new research from the drug company Moderna suggests its new mpox vaccine, based on mRNA technology, might do a. WEDNESDAY, Sept.

Vaccine 246

Vaccine Trials Virus Research 246

Drugs.com

JUNE 10, 2024

Food and Drug Administration on Friday has for the first time approved the use of a respiratory syncytial virus (RSV) vaccine for people in their 50s who are at increased risk for the illness. MONDAY, June 10, 2024 -- The U.S. Drugmaker GSK's.

Vaccine 246

Vaccine Virus FDA Drugs 246

BioPharma Drive: Drug Pricing

DECEMBER 17, 2024

An FDA approval of Merck’s drug clesrovimab by June would give physicians another option for protecting newborns from respiratory syncytial virus.

FDA 237

FDA FDA Approval Virus Drugs 237

Drugs.com

APRIL 17, 2024

WEDNESDAY, April 17, 2024 -- In a new study, people living with HIV who got standard meds to keep the virus at bay also had much lower rates of Alzheimer's disease -- suggesting the drugs might also lower risks for the brain illness.It's.

Virus 246

Virus Disease Drugs 246

Science Daily: Pharmacology News

AUGUST 9, 2023

The drug tecovirimat is currently in use for the treatment of mpox -- the disease caused by monkeypox virus -- that spread worldwide in 2022. Tecovirimat is an anti-poxviral drug, and its use is driving the emergence of drug-resistant variants of the monkeypox virus.

Licensing 161

Licensing Licensing Treatment Virus 161

Drugs.com

SEPTEMBER 22, 2023

22, 2023 -- Women may soon have a vaccine they can take during a pregnancy to help protect their newborn from respiratory syncytial virus (RSV). Food and Drug Administration, the Centers for. FRIDAY, Sept. Following approval one month ago by the U.S.

Vaccine 214

Vaccine Virus Drugs 214

Covalent Modifiers

FEBRUARY 25, 2025

The resulting compounds displayed antiviral activity against live virus that was irreversible after washout due to the covalent binding mechanism. These results highlight the potential of this screening platform for developing covalent macrocyclic drugs that disrupt proteinprotein interactions with long lasting effects.

Metabolic Stability 100

Metabolic Stability Virus Disease Drugs 100

Drugs.com

AUGUST 22, 2023

22, 2023 -- Women may soon have a vaccine they can take during a pregnancy to help protect their newborn from respiratory syncytial virus (RSV), following U.S. Food and Drug Administration approval of the shot, called Abrysvo, on. TUESDAY, Aug.

Vaccine 189

Vaccine FDA Approval Virus FDA 189

Drugs.com

AUGUST 22, 2023

22, 2023 -- Women may soon have a vaccine they can take during a pregnancy to help protect their newborn from respiratory syncytial virus (RSV), following U.S. Food and Drug Administration approval of the shot, called Abrysvo, on. TUESDAY, Aug.

FDA Approval 189

FDA Approval Vaccine Virus FDA 189

Chemical Biology and Drug Design

NOVEMBER 20, 2023

Abstract The human immunodeficiency virus type 1 (HIV-1) Gag protein is responsible for facilitating HIV-1 virion assembly and budding. Furthermore, this study has the potential to contribute to the development of drugs in the future.

Virus 100

Virus Drugs Research 100

Covalent Modifiers

MARCH 13, 2024

Second-generation oral drugs that retain function against these mutants are thus urgently needed. We hypothesized that the covalent hepatitis C virus protease inhibitor boceprevir (BPV) could serve as the basis for orally bioavailable drugs that inhibit SARS-CoV-2 Mpro more efficiently than existing drugs.

Pharmacokinetics 162

Pharmacokinetics Virus Treatment Drugs 162

Drug Discovery Today

MARCH 16, 2020

Earlier this year, the lab of Xavier Saelens (VIB-UGent) announced the discovery of a unique single-domain antibody (VHH) that is capable of binding the SARS-CoV-2 Spike protein of the COVID-19 virus. This antibody was developed in collaboration with two research groups in the US.

Virus 154

Virus Research Drugs 154

Drugs.com

JULY 17, 2023

MONDAY, July 17, 2023 (HealthDay Now) -- Parents now have a new long-acting drug to protect their children against respiratory syncytial virus (RSV), a common germ that hospitalizes as many as 3% of children under the age of 1 in the United States.

FDA Approval 100

FDA Approval Virus FDA Hospitals 100

biobide

JUNE 9, 2023

Therefore, when developing a new drug or chemical compound, it is crucial to ensure that it does not interfere with this intricate system. The immune system is the body's mechanism of defense against harmful pathogens such as bacteria, viruses, and fungi, to abnormal cells and plays an adamant role in tissue repair after damage.

Virus 96

Virus Drugs 96

Drugs.com

JUNE 9, 2023

Food and Drug Administration advisory panel on Thursday recommended that the agency approve an RSV vaccine for infants and some toddlers. The monoclonal antibody shot would protect against respiratory syncytial virus. FRIDAY, June 9, 2023 – A U.S.

Vaccine 130

Vaccine FDA Virus Drugs 130

Drug Discovery Today

MAY 10, 2021

A new approach to tackling viruses by targeting the ‘control centre’ in viral RNA could lead to broad spectrum anti-viral drugs and provide a first line of defence against future pandemics, according to new research at the University of Birmingham.

RNA 100

RNA Virus Drugs Research 100

The Pharma Data

MARCH 23, 2022

To treat Ebola virus infections, researchers are taking a close look at a key piece of the virus: polymerase. Polymerase is a viral protein that directs how Ebola virus replicates its genome as it infects new hosts. Drugs that target polymerase could potentially treat Ebola virus infections and save lives.

Virus 52

Virus Small Molecule Protein Production Research 52

SCIENMAG: Medicine & Health

JULY 21, 2023

LA JOLLA (July 21, 2023)—Salk Institute researchers, in collaboration with the National Institutes of Health, have discovered the molecular mechanisms by which the human immunodeficiency virus (HIV) becomes resistant to Dolutegravir, one of the most effective, clinically used antiviral drugs for treating HIV.

Virus 83

Virus Drugs Research 83

DrugBank

JUNE 13, 2024

The landscape of medicine is constantly evolving, and one of the most exciting areas of progress lies in the development of advanced drug delivery systems. These microscopic particles, which are smaller than 100 nanometers, can be engineered to deliver drugs to specific targets with precision.   Take cancer treatment, for example.

Therapies 98

Therapies Drugs DNA Treatment 98

Broad Institute

JULY 11, 2024

Targeted drug treatment leads tumor cells to imitate viral infection By Ari Navetta July 11, 2024 Breadcrumb Home Targeted drug treatment leads tumor cells to imitate viral infection Exploiting "viral mimicry," mIDH1 inhibitors trick tumors into thinking they are infected with a virus.

Treatment 72

Treatment Immune Response Drugs Virus 72

NIH Director's Blog: Drug Discovery

NOVEMBER 5, 2020

Because SARS-CoV-2 is so highly infectious, basic researchers without access to specially designed biosafety facilities may be limited in their ability to study the virus. While the quantum dots may bind and enter human cells just like the virus, they can’t cause an infection. But these harmless quantum dots offer a safe workaround.

Research Laboratories 85

Research Laboratories Laboratories Science Drugs 85

Chemical Biology and Drug Design

DECEMBER 13, 2023

Abstract As an expert in the field of drug design and discovery, I tried, in this up-to-date perspective or commentary article, to recap and shed light on the previous and latest revolutionary strategies employed in medicinal and therapeutic chemistry to target the principal viral weapon used by virulent RNA viruses (e.g.,

RNA 100

RNA Disease Virus Drugs 100

Chemical Biology and Drug Design

OCTOBER 10, 2023

Abstract Human immunodeficiency virus (HIV) causes acquired immunodeficiency syndrome (AIDS), a lethal disease that is prevalent worldwide. Viral reverse transcriptase (RT) is an excellent target for drug intervention. Nucleoside reverse transcriptase inhibitors (NRTIs) were the first class of approved antiretroviral drugs.

FDA Approval 100

FDA Approval Clinical Trials FDA Virus 100

SCIENMAG: Medicine & Health

AUGUST 2, 2023

Researchers at the University of Colorado Anschutz Medical Campus have helped confirm the dosing, safety and effectiveness of a drug formulation designed for treating children with human immunodeficiency virus (HIV).

Treatment 63

Treatment Virus Drugs Research 63

The Pharma Data

JANUARY 6, 2021

A Novel Ebola Virus VP40 Matrix Protein-Based Screening for Identification of Novel Candidate Medical Countermeasures.’ The published study results showed that OYA1 was “highly effective” in reducing the spread of Ebola Virus infection in laboratory tests with the live Ebola virus carried out by NIAID.

Virus 40

Virus Clinical Trials Government Laboratories 40

The Pharma Data

AUGUST 15, 2021

Food and Drug Administration were based on mRNA, more conventional protein-based vaccines have also shown promise in clinical trials. Although the first vaccines to receive Emergency Use Authorization by the U.S. So the team made polymersomes that were similar in size to SARS-CoV-2 and decorated them with many RBDs.

Vaccine 52

Vaccine Virus Immune Response Clinical Trials 52

Alta Sciences

SEPTEMBER 20, 2023

Altasciences Chosen by Virpax to Support the Development of a New Drug to Prevent Spread of Flu-like Viruses pmjackson Wed, 09/20/2023 - 13:48 Laval, Québec, September 21, 2023 - Altasciences is pleased to have been chosen by Virpax Pharmaceuticals, Inc. Altasciences helps sponsors get better drugs to the people who need them, faster.

Virus 40

Virus Clinical Pharmacology Drugs FDA Approval 40

Drug Target Review

JUNE 28, 2023

1 Over the last decade, CRISPR-Cas9 has proven immensely valuable in drug discovery and drug manufacturing. Furthermore, scientists can also use CRISPR-Cas9 to unravel mechanisms of drug resistance by identifying the set of genes associated with immune system evasion.

Engineering 98

Engineering DNA Immune Response RNA 98

Chemical Biology and Drug Design

APRIL 18, 2023

Certain target-based drugs that target specific biochemical processes of the causative parasites have been described as potential antichagasic agents that possesses various types of heterocyclic scaffolds. cruzi drugs that will give a food for thought to medicinal chemists thriving to design and develop such drugs.

Treatment 100

Treatment Disease Virus Therapies 100

ASPET

AUGUST 8, 2024

Lenacapavir (LEN), a long-acting injectable, is the first approved human immunodeficiency virus type 1 capsid inhibitor and one of a few FDA-approved drugs that exhibit atropisomerism. LEN does not distribute to brain, consistent with being a P-glycoprotein (P-gp) substrate.

Pharmacogenetics 100

Pharmacogenetics Pharmacokinetics FDA Approval Virus 100